{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:17:33Z","timestamp":1792282653538,"version":"4.4.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) remains a high-fatality cancer with limited effective therapies. CTNNB1 mutations, frequently observed in HCC, are associated with poor prognosis and immune evasion. CTNNB1 has long been considered an undruggable target due to its structural characteristics and extensive protein interactions. Porphyrin lipid nanoparticles (porphyrin-LNPs) are capable of targeting liver tumor cells, and their inherent autofluorescence allows evaluation of nanoparticle biodistribution in the liver. Our goal was to formulate a porphyrin-LNP encapsulating CTNNB1-targeting siRNA, as a novel strategy to target \u03b2-catenin-driven HCCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed porphyrin-LNPs for systemic delivery of CTNNB1-targeting siRNA. Porphyrin-LNPs were synthesized via microfluidic rapid mixing and characterized by cryo-TEM and dynamic light scattering. Their delivery efficacy was validated in HCC cell lines (Hep3B, HepG2), and their therapeutic potential was evaluated in a murine model of CTNNB1\/KRAS-driven HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Porphyrin-LNPs showed high encapsulation efficiency (97%) and effective siRNA delivery\n                      <jats:italic>in vitro<\/jats:italic>\n                      . Treatment with porphyrin-LNP-si-CTNNB1 resulted in approximately 90% downregulation of\n                      <jats:italic>CTNNB1<\/jats:italic>\n                      expression (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.0001 in Hep3B at 50nM;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.0001 in HepG2 at 10nM) and significantly reduced clonogenic survival in both Hep3B (50% reduction at 50nM,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.0001) and HepG2 (75% reduction at 10nM,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001) cell lines.\n                      <jats:italic>In vivo<\/jats:italic>\n                      , porphyrin-LNP-si-CTNNB1 significantly reduced tumor burden by approximately 67% (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.0001), liver-to-body weight ratio by 50% (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.0001), histological tumor grade, and \u03b2-catenin expression in CTNNB1\/KRAS-driven HCC mice by approximately 58% (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated that porphyrin-LNPs can effectively deliver siRNA to silence CTNNB1, an oncogene that has so far been undruggable in HCC. Future studies should explore biodistribution, immune modulation, and combination strategies to enhance clinical translatability of CTNNB1-targeted RNA interference in HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1779803","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:32:19Z","timestamp":1778214739000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A novel auto-fluorescent porphyrin-lipid nanoparticle strategy for CTNNB1 gene silencing in hepatocellular carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Jeffrey C.","family":"To","sequence":"first","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network","place":["Toronto, ON, Canada"]},{"name":"Princess Margaret Cancer Centre, University Health Network","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Apilan","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network","place":["Toronto, ON, Canada"]},{"name":"Princess Margaret Cancer Centre, University Health Network","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pasini","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network","place":["Toronto, ON, Canada"]},{"name":"Princess Margaret Cancer Centre, University Health Network","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Mo","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network","place":["Toronto, ON, Canada"]},{"name":"Division of Gastroenterology and Hepatology, Toronto General Hospital, Health Network","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Bakrania","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network","place":["Toronto, ON, Canada"]},{"name":"Princess Margaret Cancer Centre, University Health Network","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachuan","family":"Bu","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni","family":"Pan","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oyedele","family":"Adeyi","sequence":"additional","affiliation":[{"name":"Department of Pathology and University of Minnesota Medical Center, University of Minnesota","place":["Minneapolis, MN, United States"]},{"name":"Anatomic Pathology, The University of Alabama at Birmingham","place":["Alabama, AL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network","place":["Toronto, ON, Canada"]},{"name":"Division of Gastroenterology and Hepatology, Toronto General Hospital, Health Network","place":["Toronto, ON, Canada"]},{"name":"Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network","place":["Toronto, ON, Canada"]},{"name":"Princess Margaret Cancer Centre, University Health Network","place":["Toronto, ON, Canada"]},{"name":"Department of Medical Biophysics, University of Toronto","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamatha","family":"Bhat","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network","place":["Toronto, ON, Canada"]},{"name":"Princess Margaret Cancer Centre, University Health Network","place":["Toronto, ON, Canada"]},{"name":"Division of Gastroenterology and Hepatology, Toronto General Hospital, Health Network","place":["Toronto, ON, Canada"]},{"name":"Department of Medicine, University of Toronto.","place":["Toronto, ON, Canada"]},{"name":"Division of Gastroenterology & Hepatology, University of Toronto","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab079","article-title":"The mortality and overall survival trends of primary liver cancer in the United States","volume":"113","author":"Lee","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215280","article-title":"Sorafenib resistance contributed by IL7 and MAL2 in hepatocellular carcinoma can be overcome by autophagy-inducing stapled peptides","volume":"15","author":"To","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i37.13453","article-title":"Interventional treatment for unresectable hepatocellular carcinoma","volume":"20","author":"Murata","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28832","article-title":"Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model","volume":"120","author":"Flemming","year":"2014","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14040370","article-title":"MASLD-related HCC-update on pathogenesis and current treatment options","volume":"14","author":"Leyh","year":"2024","journal-title":"J Pers Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.14740\/gr1074w","article-title":"Missed diagnosis of liver cirrhosis leads to disparities in care for older patients","volume":"11","author":"Guss","year":"2018","journal-title":"Gastroenterol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000042","article-title":"Cancer and liver cirrhosis: implications on prognosis and management","volume":"1","author":"Pinter","year":"2016","journal-title":"ESMO Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15990","article-title":"Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: impact on pharmacokinetics and drug-drug interactions","volume":"90","author":"Armani","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2025.2451429","article-title":"Cirrhosis and complications hepatocellular carcinoma - expanding indications for immunotherapy","volume":"79","author":"Degroote","year":"2024","journal-title":"Acta Clin Belg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2023.07.012","article-title":"Targeting Wnt-\u03b2-catenin signaling pathway for hepatocellular carcinoma nanomedicine","volume":"2","author":"Bakrania","year":"2023","journal-title":"Gastro Hep Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-16-0309","article-title":"Direct pharmacological inhibition of beta-catenin by RNA interference in tumors of diverse origin","volume":"15","author":"Ganesh","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1038\/s41467-025-60457-2","article-title":"Precision targeting of \u03b2-catenin induces tumor reprogramming and immunity in hepatocellular cancers","volume":"16","author":"Lehrich","year":"2025","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101148","article-title":"Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1466337","article-title":"Composition of lipid nanoparticles for targeted delivery: application to mRNA therapeutics","volume":"15","author":"Vasileva","year":"2024","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c10936","article-title":"Light-activated siRNA endosomal release (LASER) by porphyrin lipid nanoparticles","volume":"17","author":"Mo","year":"2023","journal-title":"ACS Nano"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2014.04.012","article-title":"Porphysome nanotechnology: a paradigm shift in lipid-based supramolecular structures","volume":"9","author":"Huynh","year":"2014","journal-title":"Nano Today"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00272","article-title":"Targeted molecular profiling of circulating cell-free DNA in patients with advanced hepatocellular carcinoma","volume":"7","author":"Cowzer","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat Genet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27198","article-title":"Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification","volume":"60","author":"Ahn","year":"2014","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28638","article-title":"Genotype-phenotype correlation of CTNNB1 mutations reveals different ss-catenin activity associated with liver tumor progression","volume":"64","author":"Rebouissou","year":"2016","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241299678","article-title":"Prognostic impact of primary versus secondary resistance to sorafenib in patients with HCC","volume":"17","author":"Lei","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107135","article-title":"Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma","volume":"89","author":"Xie","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-21-259","article-title":"Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining","volume":"12","author":"Zhou","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.15.8847","article-title":"Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas","volume":"95","author":"de La Coste","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.14718","article-title":"Inhibition of wnt\/beta-catenin signaling in hepatocellular carcinoma by an antipsychotic drug pimozide","volume":"12","author":"Fako","year":"2016","journal-title":"Int J Biol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.02.023","article-title":"Deleting the beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth","volume":"77","author":"Loesch","year":"2022","journal-title":"J Hepatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.27.485965","article-title":"CRISPR-induced exon skipping of beta-catenin reveals tumorigenic mutants driving distinct subtypes of liver cancer","volume":"259","author":"Mou","year":"2023","journal-title":"J Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2023.07.012","article-title":"Targeting Wnt-beta-catenin signaling pathway for hepatocellular carcinoma nanomedicine","volume":"2","author":"Bakrania","year":"2023","journal-title":"Gastro Hep Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nmat2986","article-title":"Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents","volume":"10","author":"Lovell","year":"2011","journal-title":"Nat Mater"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/wnan.1247","article-title":"Assessing the barriers to image-guided drug delivery","volume":"6","author":"Lanza","year":"2014","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c08108","article-title":"Complementing cancer photodynamic therapy with ferroptosis through iron oxide loaded porphyrin-grafted lipid nanoparticles","volume":"15","author":"Liang","year":"2021","journal-title":"ACS Nano"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.0c05617","article-title":"Perfluorocarbon@porphyrin nanoparticles for tumor hypoxia relief to enhance photodynamic therapy against liver metastasis of colon cancer","volume":"14","author":"Liang","year":"2020","journal-title":"ACS Nano"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.5c16025","article-title":"Structural change of ApoE-lipid nanoparticles alters receptor-mediated endocytosis and induces endosomal disruption","volume":"148","author":"Mo","year":"2026","journal-title":"J Am Chem Soc"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s532246","article-title":"Advances in lipid-based nanomedicine: pathway specific siRNA therapy and optimizing delivery for hepatocellular carcinoma","volume":"20","author":"Thalij","year":"2025","journal-title":"Int J Nanomed"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2174\/0115672018292331240404070236","article-title":"Lipid nanoparticles as a platform for miRNA and siRNA delivery in hepatocellular carcinoma","volume":"22","author":"Dogheim","year":"2025","journal-title":"Curr Drug Delivery"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3851\/imp3361","article-title":"Antiviral activity of PLK1-targeting siRNA delivered by lipid nanoparticles in HBV-infected hepatocytes","volume":"25","author":"Foca","year":"2020","journal-title":"Antivir Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41419-020-2571-4","article-title":"Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease","volume":"11","author":"Woitok","year":"2020","journal-title":"Cell Death Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1493","article-title":"Lipoprotein-like nanoparticle carrying small interfering RNA against spalt-like transcription factor 4 effectively targets hepatocellular carcinoma cells and decreases tumor burden","volume":"4","author":"Cruz","year":"2020","journal-title":"Hepatol Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.021","article-title":"Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis","volume":"79","author":"Wang","year":"2023","journal-title":"J Hepatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2017.02.010","article-title":"Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles","volume":"251","author":"Yamamoto","year":"2017","journal-title":"J Control Release"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.01.021","article-title":"Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo","volume":"331","author":"Younis","year":"2021","journal-title":"J Control Release"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2021.12.016","article-title":"Macrophage membrane- and cRGD-functionalized thermosensitive liposomes combined with CPP to realize precise siRNA delivery into tumor cells","volume":"27","author":"Nai","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.04.028","article-title":"Modified ASO conjugates encapsulated with cytidinyl\/cationic lipids exhibit more potent and longer-lasting anti-HCC effects","volume":"32","author":"Pan","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2024.114318","article-title":"Co-delivery of SN38 and MEF2D-siRNA via tLyp-1-modified liposomes reverses PD-L1 expression induced by STING activation in hepatocellular carcinoma","volume":"245","author":"Du","year":"2025","journal-title":"Colloids Surf B Biointerfaces"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.11.012","article-title":"GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma","volume":"32","author":"Neumayer","year":"2024","journal-title":"Mol Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1779803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:32:22Z","timestamp":1778214742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1779803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":51,"alternative-id":["10.3389\/fonc.2026.1779803"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1779803","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1779803"}}